EPICOVIDEHA study group, Aiello, TF, Salmanton-García, J, Marchesi, F, Weinbergerová, B, Glenthøj, A, Van Praet, J, Farina, F, Dávila-Valls, J, Martín-Pérez, S, El-Ashwah, S, Schönlein, M, Falces-Romero, I, Labrador, J, Sili, U, Buquicchio, C, Vena, A, Plantefeve, G, Petzer, V, Biernat, MM, Lahmer, T, Espigado, I
, Van Doesum, J, Blennow, O, Piukovics, K, Tascini, C, Samarkos, M, Bilgin, YM, Fianchi, L, Itri, F, Valković, T, Fracchiolla, NS, Dargenio, M, Jiménez, M, Magyari, F, López-García, A, Prezioso, L, Čolović, N, Shumilov, E, Abu-Zeinah, G, Krekeler, C, Lavilla-Rubira, E, Papa, MV, González-López, TJ, Pinczés, LI, Demirkan, F, Ali, N, Besson, C, Fouquet, G, Da Silva, MG
, Ammatuna, E & Pagano, L 2024, '
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry',
Haematologica, vol. 109, nr. 8, blz. 2693-2700.
https://doi.org/10.3324/haematol.2023.284678